Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2021
April 2021, Vol 12, No 2
April 2021, Vol 12, No 2
Abemaciclib Added to Endocrine Therapy Reduces Invasive Disease Recurrence in High-Risk HR-Positive Early Breast Cancer: monarchE
By
Phoebe Starr
Breast Cancer
April 2021, Vol 12, No 2
The addition of the cyclin-dependent kinase (CDK)4/6 inhibitor abemaciclib (Verzenio) to standard endocrine therapy reduced the risk for invasive disease recurrence or death compared with endocrine therapy alone by almost 30% in patients with high-risk, hormone receptor (HR)-positive, HER2-negative early breast cancer. These results come from the primary analysis of the phase 3 monarchE clinical trial that was presented at the 2020 San Antonio Breast Cancer Symposium.
Read More
Later Diagnoses, Worse Outcomes in Patients with Lung Cancer During COVID-19 May Last
By
Walter Alexander
COVID-19
,
Lung Cancer
April 2021, Vol 12, No 2
The COVID-19 pandemic has had a profound impact on healthcare, especially in the management of patients with cancer, who are often not seeking healthcare in the same way as before the pandemic. At the 2021 International Association for the Study of Lung Cancer (IASLC) meeting, experts discussed the implications for patients with lung cancer, specifically.
Read More
Bemarituzumab, FGFR2b Inhibitor, Improves Survival in Advanced Gastric Cancer with FGFR2b Mutation
By
Wayne Kuznar
ASCO 2021 Highlights
April 2021, Vol 12, No 2
Bemarituzumab, an investigational first-in-class humanized immunoglobulin G1 monoclonal antibody that selectively binds to
FGFR2b
, improved progression-free survival (PFS) and overall survival (OS) when added to the modified FOLFOX6 (mFOLFOX6) chemotherapy in patients with
FGFR2b
-positive advanced gastric or gastroesophageal junction (GEJ) cancer in the phase 2 FIGHT randomized clinical trial. The results were presented at the 2021 ASCO Gastrointestinal Cancers Symposium.
Read More
FDA Approved Abecma, First CAR T-Cell Therapy for Multiple Myeloma
FDA Approvals, News & Updates
April 2021, Vol 12, No 2
On
March 27, 2021
, the FDA approved idecabtagene vicleucel (Abecma; Bristol Myers Squibb/Bluebird Bio), a B-cell maturation antigen (BCMA)-directed, genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or recurred, after ≥4 lines of therapy. Idecabtagene vicleucel is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. The FDA granted this indication orphan drug and breakthrough therapy designations.
Read More
Nivolumab Monotherapy Extends Survival in Patients with Relapsed Malignant Mesothelioma
By
Walter Alexander
Mesothelioma
April 2021, Vol 12, No 2
For patients with relapsed malignant mesothelioma, nivolumab (Opdivo) monotherapy is an effective treatment option, according to preliminary results of the phase 3 CONFIRM study, presented at the 2021 International Association for the Study of Lung Cancer meeting.
Read More
EGFR Most Common Mutation in Women with Lung Cancer and No Smoking History
By
Walter Alexander
Lung Cancer
April 2021, Vol 12, No 2
Genomic analysis of lung cancer in women who have never smoked may reveal novel mutations and structural alterations. Such an analysis, said Sitapriya Moorthi, PhD, Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, may suggest unique opportunities for future target identification and therapeutic intervention. Dr Moorthi discussed the results of a mutational analysis of the Women’s Health Initiative Cohort that were presented at the 2021 International Association for the Study of Lung Cancer meeting.
Read More
Sotorasib, First-in-Class KRAS p.G12C Inhibitor, Induces Durable Responses in Patients with Advanced NSCLC
By
Walter Alexander
Lung Cancer
April 2021, Vol 12, No 2
Approximately 13% of patients with lung adenocarcinomas harbor
KRAS
p.G12C mutations. In the phase 2 CodeBreaK 100 clinical trial, the responses to sotorasib in patients with advanced non–small-cell lung cancer (NSCLC) and
KRAS
p.G12C mutation were early, deep, and durable, according to Bob T. Li, MD, PhD, MPH, Medical Oncologist, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. He presented the study results at the 2021 International Association for the Study of Lung Cancer meeting.
Read More
Enfortumab Vedotin Extends Survival in Metastatic Urothelial Cancer
By
Phoebe Starr
ASCO 2021 Highlights
April 2021, Vol 12, No 2
In patients with metastatic urothelial cancer who received previous therapy, as well as in cisplatin-ineligible patients with this cancer, enfortumab vedotin-ejfv (Padcev) improved overall survival (OS), according to new data presented at the 2021 ASCO Genitourinary Cancers Symposium. The data come from the phase 3 EV-301 study and cohort 2 of the phase 2 EV-201 study. Experts believe this antibody–drug conjugate will become a new standard of care in the treatment of patients with advanced urothelial cancer.
Read More
LGBT Populations: Lung Cancer Screening Disparities Linked to Sexual Orientation
By
Walter Alexander
Lung Cancer
April 2021, Vol 12, No 2
Sexual orientation and assigned sex at birth are significant determinants in the utilization of lung cancer screening, according to an analysis from the Behavioral Risk Factor Surveillance System (BRFSS) 2018, a cross-sectional, nationally representative database, that looked at screening among lesbian, gay, bisexual, transgender (LGBT) populations.
Read More
Patients with Lung Cancer Distressed About Impact of COVID-19 on Access to Care
By
Walter Alexander
COVID-19
April 2021, Vol 12, No 2
A survey of patients with lung cancer conducted as COVID-19 pandemic shelter-in-place lockdowns were first easing in June 2020 in the United States revealed substantial anxieties about vulnerability to severe illness and access to care.
Read More
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma